Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway
• Over 50% reduction in personnel • Cost reductions expected to extend the cash runway into the first half of 2023 • The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022 BOSTON and HOUSTON , Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc.
View HTML
Toggle Summary Ziopharm Oncology to Participate in September Investor Conferences
BOSTON and HOUSTON , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle , Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences: 2021 Wells Fargo
View HTML
Toggle Summary Ziopharm Oncology Appoints Kevin S. Boyle, Sr., as Chief Executive Officer and Announces other Executive Promotions
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D.
View HTML
Toggle Summary Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank , strengthening balance sheet and e xtending cash runway into the
View HTML
Toggle Summary Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
BOSTON , July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9 , at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021 .
View HTML
Toggle Summary Ziopharm Oncology to Participate in Upcoming Conferences
BOSTON , May 24, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage cellular therapy company focused on hematologic and solid tumor cancers, today announced that Company management will participate in two upcoming investor conferences:
View HTML
Toggle Summary Ziopharm Oncology Reinforces Clear and Bold Vision for Delivering Value at Annual Shareholders Meeting
– Highlighted distinctive cellular therapy program, market opportunity and value proposition –   Shared optimistic outlook and commitment to deliver value to shareholders –   Encouraged by overwhelming vote of shareholders in favor of the Company proposals on all matters BOSTON , May 19, 2021
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates
– Annual shareholder meeting planned for May 19, 2021 –   Company to host conference call today at 4:30 pm ET   BOSTON , May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial results for the first quarter ended March
View HTML
Toggle Summary Ziopharm Oncology Scientific Advisor Laurence Cooper, MD, PhD, to Present at University of Pennsylvania Cellicon Valley ’21 Two-Day Live Virtual Educational Symposium
Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event BOSTON , May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper , PhD, MD, Scientific Advisor to the Company, will present and
View HTML
Toggle Summary Ziopharm Oncology to Report First Quarter Financial Results on May 6, 2021
Annual shareholder meeting to be held on May 19, 2021 BOSTON , April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder
View HTML